CN104774270A - 一种腺癌特异性EpCAM-GM-CSF基因重组融合蛋白及其制备方法 - Google Patents
一种腺癌特异性EpCAM-GM-CSF基因重组融合蛋白及其制备方法 Download PDFInfo
- Publication number
- CN104774270A CN104774270A CN201510227558.8A CN201510227558A CN104774270A CN 104774270 A CN104774270 A CN 104774270A CN 201510227558 A CN201510227558 A CN 201510227558A CN 104774270 A CN104774270 A CN 104774270A
- Authority
- CN
- China
- Prior art keywords
- epcam
- csf
- hgm
- fusion rotein
- purifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 20
- 208000009956 adenocarcinoma Diseases 0.000 title claims abstract description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract description 11
- 230000002068 genetic effect Effects 0.000 title abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 47
- 239000013612 plasmid Substances 0.000 claims abstract description 36
- 239000013598 vector Substances 0.000 claims abstract description 28
- 241000588724 Escherichia coli Species 0.000 claims abstract description 20
- 238000012216 screening Methods 0.000 claims abstract description 11
- 230000004927 fusion Effects 0.000 claims description 64
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 57
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 57
- 241000894006 Bacteria Species 0.000 claims description 52
- 239000007788 liquid Substances 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- 239000006228 supernatant Substances 0.000 claims description 30
- 108091008146 restriction endonucleases Proteins 0.000 claims description 28
- 230000006698 induction Effects 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 24
- 238000012408 PCR amplification Methods 0.000 claims description 22
- 238000011144 upstream manufacturing Methods 0.000 claims description 21
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 20
- 235000018102 proteins Nutrition 0.000 claims description 19
- 238000012797 qualification Methods 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 239000003292 glue Substances 0.000 claims description 18
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 210000004907 gland Anatomy 0.000 claims description 14
- 150000002460 imidazoles Chemical class 0.000 claims description 13
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 12
- 229920002684 Sepharose Polymers 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 239000002299 complementary DNA Substances 0.000 claims description 11
- 235000015097 nutrients Nutrition 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 9
- 238000013461 design Methods 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 238000002525 ultrasonication Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 230000004544 DNA amplification Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 7
- 238000001962 electrophoresis Methods 0.000 claims description 7
- 239000012160 loading buffer Substances 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 230000009466 transformation Effects 0.000 claims description 7
- 239000011534 wash buffer Substances 0.000 claims description 7
- 101150084967 EPCAM gene Proteins 0.000 claims description 6
- 239000013642 negative control Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 230000035939 shock Effects 0.000 claims description 6
- 102000003960 Ligases Human genes 0.000 claims description 5
- 108090000364 Ligases Proteins 0.000 claims description 5
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000012149 elution buffer Substances 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000010189 synthetic method Methods 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000010186 staining Methods 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 claims description 2
- 230000007969 cellular immunity Effects 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000013519 translation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 10
- 102000037865 fusion proteins Human genes 0.000 abstract description 8
- 108020001507 fusion proteins Proteins 0.000 abstract description 8
- 238000012163 sequencing technique Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 44
- 239000000427 antigen Substances 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 229940029030 dendritic cell vaccine Drugs 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 230000003139 buffering effect Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 229940030156 cell vaccine Drugs 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940051921 muramidase Drugs 0.000 description 2
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960002203 tilactase Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 108010046845 tryptones Proteins 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 101150038172 1.2 gene Proteins 0.000 description 1
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000148131 Colibacter Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- KHWCHTKSEGGWEX-UHFFFAOYSA-N deoxyadenylic acid Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(O)=O)O1 KHWCHTKSEGGWEX-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510227558.8A CN104774270B (zh) | 2015-05-06 | 2015-05-06 | 一种腺癌特异性EpCAM‑GM‑CSF基因重组融合蛋白及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510227558.8A CN104774270B (zh) | 2015-05-06 | 2015-05-06 | 一种腺癌特异性EpCAM‑GM‑CSF基因重组融合蛋白及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104774270A true CN104774270A (zh) | 2015-07-15 |
CN104774270B CN104774270B (zh) | 2017-08-08 |
Family
ID=53616060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510227558.8A Active CN104774270B (zh) | 2015-05-06 | 2015-05-06 | 一种腺癌特异性EpCAM‑GM‑CSF基因重组融合蛋白及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104774270B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106967157A (zh) * | 2017-03-09 | 2017-07-21 | 南昌大学 | 一种pBpp蛋白及其功能验证方法 |
CN106967156A (zh) * | 2017-03-09 | 2017-07-21 | 南昌大学 | 一种针对pBpp蛋白的纯化方法 |
CN107090425A (zh) * | 2017-04-25 | 2017-08-25 | 中国药科大学 | 一种重组mGM-CSF与GRP6融合蛋白的基因工程菌的构建 |
CN107236762A (zh) * | 2017-06-19 | 2017-10-10 | 河北浓孚雨生物科技有限公司 | 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法 |
WO2019062790A1 (en) * | 2017-09-29 | 2019-04-04 | Lan Keng Li | NEW CONJUGATES AND ASSOCIATED USES |
CN109942719A (zh) * | 2019-05-07 | 2019-06-28 | 中国人民解放军陆军军医大学第二附属医院 | 一种金黄色葡萄球菌融合蛋白及其蛋白表达载体和纯化方法 |
CN111394359A (zh) * | 2020-03-23 | 2020-07-10 | 西南大学 | 朱砂叶螨钙调蛋白基因的克隆、原核表达和蛋白纯化方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103755812A (zh) * | 2012-12-14 | 2014-04-30 | 上海柯莱逊生物技术有限公司 | 一种gm-csf-her2重组蛋白及其方法和应用 |
CN103788213A (zh) * | 2012-12-14 | 2014-05-14 | 上海柯莱逊生物技术有限公司 | 一种gm-csf-tat-cea重组蛋白及其方法和应用 |
-
2015
- 2015-05-06 CN CN201510227558.8A patent/CN104774270B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103755812A (zh) * | 2012-12-14 | 2014-04-30 | 上海柯莱逊生物技术有限公司 | 一种gm-csf-her2重组蛋白及其方法和应用 |
CN103788213A (zh) * | 2012-12-14 | 2014-05-14 | 上海柯莱逊生物技术有限公司 | 一种gm-csf-tat-cea重组蛋白及其方法和应用 |
Non-Patent Citations (1)
Title |
---|
孔娟: "EpCAM蛋白的表达、纯化及其单克隆抗体的制备"", <中国生物工程杂志> * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106967157A (zh) * | 2017-03-09 | 2017-07-21 | 南昌大学 | 一种pBpp蛋白及其功能验证方法 |
CN106967156A (zh) * | 2017-03-09 | 2017-07-21 | 南昌大学 | 一种针对pBpp蛋白的纯化方法 |
CN107090425A (zh) * | 2017-04-25 | 2017-08-25 | 中国药科大学 | 一种重组mGM-CSF与GRP6融合蛋白的基因工程菌的构建 |
CN107236762A (zh) * | 2017-06-19 | 2017-10-10 | 河北浓孚雨生物科技有限公司 | 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法 |
WO2019062790A1 (en) * | 2017-09-29 | 2019-04-04 | Lan Keng Li | NEW CONJUGATES AND ASSOCIATED USES |
CN111406072A (zh) * | 2017-09-29 | 2020-07-10 | 蓝耿立 | 新缀合物及其用途 |
CN109942719A (zh) * | 2019-05-07 | 2019-06-28 | 中国人民解放军陆军军医大学第二附属医院 | 一种金黄色葡萄球菌融合蛋白及其蛋白表达载体和纯化方法 |
CN111394359A (zh) * | 2020-03-23 | 2020-07-10 | 西南大学 | 朱砂叶螨钙调蛋白基因的克隆、原核表达和蛋白纯化方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104774270B (zh) | 2017-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104774270A (zh) | 一种腺癌特异性EpCAM-GM-CSF基因重组融合蛋白及其制备方法 | |
ES2264563T3 (es) | Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion. | |
CN104725515B (zh) | 一种类弹性蛋白多肽与柯萨奇腺病毒受体融合蛋白及其制备方法和应用 | |
CN110684120B (zh) | 一种靶向gpc3的嵌合抗原受体及其应用 | |
CN107847577A (zh) | 包含编码类M蛋白质的mRNA的癌症疫苗 | |
CN111606999B (zh) | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 | |
WO2020103651A1 (zh) | 间充质干细胞在制备治疗类风湿性关节炎的产品中的应用 | |
CN101063142B (zh) | 人乳头瘤病毒16型dna疫苗和基因佐剂及其应用 | |
CN104371025B (zh) | 一种针对宫颈癌具有免疫原性的蛋白及其应用 | |
CN108048483A (zh) | 复制型重组腺病毒HAdV-5载体系统及其应用 | |
CN103570836A (zh) | 一种重组猪干扰素β1-Fc融合蛋白及其编码基因和表达方法 | |
CN105861402A (zh) | 将异源蛋白呈递于大肠杆菌外膜囊泡表面的新型疫苗形式 | |
CN102816246A (zh) | 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途 | |
CN104152480A (zh) | 布鲁氏菌L7/L12、Omp31、Rsα、sodC免疫蛋白共表达载体构建和表达方法 | |
CN105420174A (zh) | 一种表达重组vegf融合蛋白的基因工程菌的构建 | |
CN105647970A (zh) | 前列腺癌特异性pap-gm-csf-il-6基因重组融合蛋白及其制备方法 | |
CN103360497A (zh) | 一种新型抗肿瘤融合蛋白疫苗及其制备方法和应用 | |
CN103232544B (zh) | 一种重组猪干扰素γ-Fc融合蛋白及其编码基因和表达方法 | |
CN103695327A (zh) | 一种口服重组酵母及其介导的靶向肠道DC呈递shRNA的应用 | |
CN103864939A (zh) | mGM-CSF/βhCG融合蛋白及其制备方法和应用 | |
CN110257314B (zh) | 一种产抗菌肽Cecropin B的重组枯草芽孢杆菌、构建方法及其应用 | |
CN107827986B (zh) | 猪O/Mya98和O/PanAsia型口蹄疫基因工程灭活疫苗 | |
CN107090425A (zh) | 一种重组mGM-CSF与GRP6融合蛋白的基因工程菌的构建 | |
CN106085932A (zh) | 一种重组VEGF与GnRH融合蛋白的基因工程菌的构建 | |
CN105176897A (zh) | 一种表达GnRH/M2融合多肽的重组工程菌株及其构建和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Cai Jianhui Inventor after: Du Pingping Inventor after: Shang Yuanyuan Inventor after: He Huijuan Inventor after: Fu Zexian Inventor before: Cai Jianhui |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 050000 Floor 1, Building 238 Changjiang Avenue, Shijiazhuang High-tech Zone, Hebei Province Patentee after: HEBEI NONGFOYU BIOLOGY TECHNOLOGY Co.,Ltd. Address before: 050035 Hongchang Industrial Park Building No. 1, Changjiang Avenue and Hengshan Street, Shijiazhuang High-tech Zone, Hebei Province Patentee before: HEBEI LITONGKANG BIOTECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211208 Address after: 050000 1st floor, building 1, Hongchang Industrial Park, No. 238 Changjiang Avenue, high tech Zone, Shijiazhuang, Hebei Patentee after: Nongfuyu pharmaceutical Hebei Co.,Ltd. Address before: 050000 floor 1, building 1, 238 Changjiang Avenue, high tech Zone, Shijiazhuang City, Hebei Province Patentee before: HEBEI NONGFOYU BIOLOGY TECHNOLOGY Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 050000 1st floor, building 1, Hongchang Industrial Park, No. 238 Changjiang Avenue, high tech Zone, Shijiazhuang, Hebei Patentee after: Nongfuyu pharmaceutical Hebei Co.,Ltd. Address before: 050000 1st floor, building 1, Hongchang Industrial Park, No. 238 Changjiang Avenue, high tech Zone, Shijiazhuang, Hebei Patentee before: Nongfuyu pharmaceutical Hebei Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231012 Address after: Room 2024, Hebei Publishing Media Creative Center, No. 19 Yuanboyuan Street, Zhengding District, China (Hebei) Free Trade Pilot Zone, Shijiazhuang City, Hebei Province, 050899 Patentee after: Yuetenong biotechnology Hebei Co.,Ltd. Address before: 050000 1st floor, building 1, Hongchang Industrial Park, No. 238 Changjiang Avenue, high tech Zone, Shijiazhuang, Hebei Patentee before: Nongfuyu pharmaceutical Hebei Co.,Ltd. |